89bio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

27 Feb 2025

ETNB

10-K: 89bio Reports Full Year 2024 Results, Highlights Progress of Pegozafermin in MASH and SHTG

89bio, a clinical-stage biopharmaceutical company, provides an update on its financial results for the year ended December 31, 2024, and highlights the advancement of its lead product candidate, pegozafermin, in clinical trials for MASH and SHTG.

1 Mar 2024

ETNB

89bio, INC

10-K: 89bio, Inc. Outlines Capital Structure and Regulatory Landscape in 10-K Filing

89bio, Inc.'s 10-K filing details its capital structure, regulatory environment, and ongoing clinical programs for pegozafermin.